Omnicell, Inc. — Q3 2014 Form 10-Q
Business context and reporting period. The filing covers the three and nine months ended September 30, 2014. Omnicell provides medication and supply automation, analytics, and medication-adherence products and services to healthcare customers. In 2014 it reorganized reporting into Automation and Analytics and Medication Adherence segments. The United States and Canada generated approximately 90% of revenue.
Financial performance
| Metric | Q3 2014 | Q3 2013 | Nine months 2014 | Nine months 2013 |
|---|---|---|---|---|
| Revenue | $112.5m | $94.0m | $319.4m | $274.8m |
| Gross profit / margin | $59.5m / 52.9% | $52.0m / 55.4% | $170.1m / 53.3% | $146.8m / 53.4% |
| Operating income / margin | $13.6m / 12.1% | $10.7m / 11.4% | $36.1m / 11.3% | $24.2m / 8.8% |
| Net income | $7.3m | $7.8m | $21.3m | $17.2m |
| Diluted EPS | $0.20 | $0.21 | $0.58 | $0.48 |
Q3 revenue increased 19.7% year over year, while nine-month revenue rose 16.2%. Q3 net income declined despite higher operating income, reflecting higher tax expense and a $0.7m net interest and other expense versus $0.03m of income in the prior-year quarter. The Q3 effective tax rate was 43.4%, compared with 27.8% a year earlier; the nine-month rates were 39.4% and 28.9%.
Segments. Q3 Automation and Analytics revenue was $89.5m, up 19.2%, with a 57.1% gross margin versus 59.7%. Medication Adherence revenue was $23.0m, up 21.5%, with a 36.6% gross margin versus 37.9%. For the nine months, the segments generated $255.7m and $63.6m of revenue, respectively.
Cash, liquidity, and obligations
- Cash and cash equivalents were $104.2m at September 30, 2014, nearly unchanged from $104.5m at year-end 2013. Total current assets were $268.4m and current liabilities $111.6m.
- Nine-month operating cash flow was $34.3m, down from $40.7m. The $35.0m increase in accounts receivable, driven by higher shipments, was a major cash use; growth in deferred gross profit partly offset it.
- Investing cash outflow was $38.1m, including $19.7m for Surgichem, $10.2m for property and equipment, and $7.9m for capitalized software development. Financing cash inflow was $3.5m, including employee equity-plan proceeds, partly offset by repurchases and employee tax payments.
- The company disclosed a $75m revolving credit facility, with no borrowings to date, and was compliant with its covenants. Management said available cash, expected operating cash flow, equity-plan proceeds, and facility availability should meet needs for at least 12 months.
- Operating lease commitments totaled $38.0m; supplier and contract-manufacturer commitments totaled $10.9m. No off-balance-sheet arrangements were reported.
Material changes, outlook, and risks
- Acquisition: Omnicell acquired UK medication-adherence provider Surgichem on August 22 for approximately $20.8m total consideration. Surgichem contributed about $1.4m of revenue and $0.1m of operating income after acquisition. Purchase-price allocation was preliminary and included $12.0m of goodwill.
- Drivers and margins: Growth reflected more customer installations, G4 upgrades, and European medication-adherence demand. Management attributed the Q3 gross-margin decline primarily to installation timing and a greater mix of large, lower-margin competitive conversions. Service efficiency benefited from G4 reliability.
- Outlook: Management anticipated 2014 revenue growth versus 2013 as it fulfilled existing orders and expected to manage the remainder of 2014 to operating profit margins similar to the nine-month level. Installation timing, customer demand, production, and staffing capacity could affect results. No specific revenue or EPS target was provided.
- Legal contingency: MV Circuit Design sued in September 2014 over inventorship of certain Omnicell patents and related claims. The company intends to defend the matter; it recorded no accrual because loss was considered reasonably possible, not probable, and said any loss range could not be reasonably estimated.
- Other risks: Healthcare capital-budget constraints and lengthy installation cycles, competition and pricing pressure, product and software quality, supplier concentration, international expansion and acquisition integration, privacy/security obligations, and intellectual-property disputes could affect results. The company also identified risks from ERP-system upgrades and adoption of future accounting standards.
Most important facts for investors to verify
- Whether the higher installation and shipment volume converts into revenue and cash on schedule; accounts receivable rose substantially and products shipped but not yet installed contributed to deferred gross profit.
- Whether Q3 gross-margin pressure from customer mix and installation timing persists, and whether segment margins recover.
- How Surgichem integration, subsequent working-capital purchase-price adjustments, and international growth affect margins and cash flow.
- Whether the elevated effective tax rate continues and how tax-credit availability affects earnings.
- Developments in the patent inventorship litigation and any change in the company’s assessment of potential loss.
- Capital allocation and liquidity: the company repurchased $19.6m of shares during the first nine months, had $9.4m remaining under its repurchase authorization, and had not drawn its revolving facility.